You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Upraxia Pharmaceuticals plans an early December Phase IIb interim readout for EP-104GI in eosinophilic esophagitis. Dose-escalation data showed 64% of patients in clinical remission at 52 weeks, while FACE-2B will extend follow-up beyond 52 weeks.
Eupraxia Pharmaceuticals announced a virtual Analyst Day on November 13, 2026 to discuss EP-104GI for Eosinophilic Esophagitis; EP-104GI is currently in a Phase 1b/2 trial.
Eupraxia reached enrollment of 120 patients in the blinded Phase 2b portion of the RESOLVE trial; over 3,000 injections have been administered with no treatment-related SAEs, and interim analysis is on track for December 2026.
Illustrative technical + ownership context — a signal mix, not investment advice.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XTSE:EPRX | -9.0% | -16.3% | -7.1% | -3.1% | -10.6% |
Company with tickers: EPRX
Share classes and depositary receipts can have different prices and dividends.
Follow EPRX during the session: the latest price, the day's change, range and volume. Closing prices stay free.
No verified dividend payments are available for this listing yet.
| Date | Event | Type |
|---|---|---|
| 2026-11-10 21:40 UTC | Stifel 2026 Healthcare Conference | Conference |
| 2026-11-13 13:30 UTC | Virtual Analyst Day to Discuss EP-104GI for Eosinophilic Esophagitis | Presentation |
| 2026-11-16 13:30 UTC | 2026 Jefferies Global Healthcare Conference in London | Conference |
